The Royal Pharmaceutical Society is entirely supportive of the provision of NHS services to young people where there is an unmet need.

Future public health service delivery will be undermined unless urgent action is taken to kick start the handover of the management of Pharmaceutical Needs Assessments from PCTs to Health and Wellbeing Boards, warns Gianpiero Celino, Consulting Practice Lead at Webstar Health.

Patients with advanced prostate cancer who were given a new type of hormonal treatment called MDV3100 lived an extra 4.8 months compared to men taking a placebo, according to the full analysis of a Phase III trial jointly led by Professor Johann de Bono from The Institute of Cancer Research (ICR) and The Royal Marsden Hospital.

The Royal College of General Practitioners (RCGP) and the Royal Pharmaceutical Society (RPS) have produced a joint statement detailing how GPs and community pharmacists can work together to improve the care provided to patients in the community.

IS Pharma is pleased to announce that from April 1st 2011 episilŽ, an oral spray indicated for local treatment of pain associated with oral mucositis, will be listed on the NHS Drug Tariff for England and Wales. This will make prescribing and patient access to treatment easier and more convenient for healthcare professionals.

Public awareness lags behind the widespread availability of pharmacy based healthcare services, a survey by the National Pharmacy Association (NPA) reveals.

The Royal College of General Practitioners (RCGP) and the Proprietary Association of Great Britain (PAGB) announced plans for an e-learning module at the joint RCGP and PAGB Expert Self Care Symposium at BMA House, London recently.

ASTRAZENECA UK receives positive decision for SEROQUEL XL (QUETIAPINE prolonged release) as an add-on treatment of major depressive disorder.

The National Institute for Health and Clinical Excellence (NICE), has issued its Final Appraisal Determination (FAD) on the use of VictozaŽ (liraglutide) for patients with Type 2 diabetes in the UK. The appraisal is part of a Single Technology Appraisal conducted by NICE

Produced by Crucell UK Ltd both vaccines are eligible for reimbursement following successful discussions with the Department of Health under section 17.4 of the statement of financial entitlement for purchase and personal administration by healthcare professionals.